Analysts expect Viking Therapeutics Inc (NASDAQ:VKTX) to post ($0.10) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Viking Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.12) and the highest estimate coming in at ($0.09). Viking Therapeutics reported earnings of ($0.14) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 28.6%. The company is expected to issue its next earnings results on Wednesday, March 6th.
According to Zacks, analysts expect that Viking Therapeutics will report full-year earnings of ($0.42) per share for the current fiscal year, with EPS estimates ranging from ($0.45) to ($0.40). For the next financial year, analysts expect that the business will post earnings of ($0.46) per share, with EPS estimates ranging from ($0.55) to ($0.34). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Viking Therapeutics.
Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.01.
Viking Therapeutics stock opened at $11.29 on Friday. Viking Therapeutics has a 52 week low of $2.53 and a 52 week high of $24.00. The stock has a market capitalization of $806.78 million, a P/E ratio of -14.29 and a beta of 2.92.
In other Viking Therapeutics news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of the company’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $19.15, for a total value of $5,034,171.15. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.90% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in VKTX. Quantbot Technologies LP purchased a new position in shares of Viking Therapeutics during the 3rd quarter worth about $109,000. First Mercantile Trust Co. purchased a new position in shares of Viking Therapeutics during the 3rd quarter worth about $131,000. Janney Montgomery Scott LLC purchased a new position in shares of Viking Therapeutics during the 2nd quarter worth about $114,000. Man Group plc purchased a new position in shares of Viking Therapeutics during the 3rd quarter worth about $211,000. Finally, Strs Ohio purchased a new position in shares of Viking Therapeutics during the 2nd quarter worth about $120,000. Institutional investors own 62.34% of the company’s stock.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
Featured Story: Different Types of Derivatives
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.